A Look Back at the Evolution in the Management of Exudative (Wet) Age-Related Macular Degeneration

SriniVas R. Sadda, MD


April 19, 2022

In the course of recalling a patient experience involving an initial aggravation of age-related macular degeneration (AMD) in order to effect a greater long-term benefit, SriniVas R. Sadda, MD, considers how the evolution of treatment for AMD has relegated such agonizing measures to the past.

Dr Sadda discusses how anti-VEGF therapy in particular has produced a far more positive clinical scene, and that vision outcomes have been dramatically improved. The result is retained physical and social functionality for patients to a degree that had previously been thought unattainable.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.